Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

• Published in: Bone marrow transplantation (Basingstoke) Vol. 40; no. 3; pp. 239 - 243
• Main Authors: SMITH, S. D, BOLWELL, B. J, SWEETENHAM, J. W, RYBICKI, L. A, BROWN, S, DEAN, R, KALAYCIO, M, SOBECKS, R, ANDRESEN, S, HSI, E. D, POHLMAN, B
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.08.2007
• Subjects: Adolescent; Adult; Aged; Anaplastic large-cell lymphoma; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Autografts; Biological and medical sciences; Bone marrow; Bone marrow, stem cells transplantation. Graft versus host reaction; Busulfan; Busulfan - administration & dosage; Cancer; Care and treatment; Chemotherapy; Cyclophosphamide; Cyclophosphamide - administration & dosage; Disease-Free Survival; Etoposide; Etoposide - administration & dosage; Female; Hematologic and hematopoietic diseases; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Heterogeneity; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphocytes B; Lymphocytes T; Lymphoma; Lymphoma, B-Cell - mortality; Lymphoma, B-Cell - therapy; Lymphoma, T-Cell - mortality; Lymphoma, T-Cell - therapy; Male; Medical sciences; Methods; Middle Aged; Non-Hodgkin's lymphoma; Retrospective Studies; Stem cell transplantation; Stem cells; Survival; Survival Rate; T cell lymphoma; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation; Transplantation Conditioning; Transplantation, Autologous; United States; Hematology; autologous bone marrow transplant; Stem cell; Hematopoietic cell; Anaplastic cell lymphoma; peripheral T-cell lymphoma; Malignant hemopathy; Large cell lymphoma; Non Hodgkin lymphoma; anaplastic large-cell lymphoma; Peripheral T cell lymphoma; Autograft; Lymphoproliferative syndrome; Bone marrow; Graft; High dose
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/sj.bmt.1705712

The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.